NASDAQ · LAB
Healthcare · Medical - Devices
$0.71
Down-$0.04 (-4.99%)
Updated Aug 17, 2026, 11:38 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LAB closed at $0.71 after 20 trading sessions, down 16.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.742 | $0.76 | $0.705 | $0.7124 | 1.31M |
| Aug 13, 2026 | $0.78 | $0.81 | $0.7449 | $0.7498 | 1.3M |
| Aug 12, 2026 | $0.7701 | $0.797 | $0.7701 | $0.7941 | 1.04M |
| Aug 11, 2026 | $0.7869 | $0.8049 | $0.7801 | $0.7875 | 450.22K |
| Aug 10, 2026 | $0.795 | $0.81 | $0.7739 | $0.7888 | 757.33K |
| Aug 7, 2026 | $0.781 | $0.822 | $0.7801 | $0.80 | 730.3K |
| Aug 6, 2026 | $0.7674 | $0.804 | $0.7674 | $0.8001 | 1.11M |
| Aug 5, 2026 | $0.805 | $0.839 | $0.779 | $0.7841 | 2.15M |
| Aug 4, 2026 | $0.87 | $0.8851 | $0.8205 | $0.8205 | 1.2M |
| Aug 3, 2026 | $0.8632 | $0.9097 | $0.8551 | $0.8662 | 1.29M |
| Jul 31, 2026 | $0.8846 | $0.9004 | $0.855 | $0.868 | 1.26M |
| Jul 30, 2026 | $0.889 | $0.9165 | $0.8552 | $0.8973 | 3.85M |
| Jul 29, 2026 | $0.781 | $0.915 | $0.7802 | $0.8739 | 3.93M |
| Jul 28, 2026 | $0.80 | $0.80 | $0.766 | $0.7947 | 3.02M |
| Jul 27, 2026 | $0.8305 | $0.852 | $0.7675 | $0.7746 | 1.61M |
| Jul 24, 2026 | $0.8753 | $0.8845 | $0.82 | $0.8332 | 994.43K |
| Jul 23, 2026 | $0.801 | $0.88 | $0.801 | $0.8753 | 2.98M |
| Jul 22, 2026 | $0.88 | $0.8999 | $0.803 | $0.8184 | 1.65M |
| Jul 21, 2026 | $0.85 | $0.8912 | $0.8353 | $0.8841 | 727.87K |
| Jul 20, 2026 | $0.9062 | $0.915 | $0.8422 | $0.85 | 1.1M |
The latest Smart Investors Daily articles mentioning LAB.
LAB research
Company profile and research snapshot.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2025 | TD Cowen | Hold | — |
| Feb 27, 2025 | Keybanc | Sector Weight | — |
| Oct 31, 2024 | TD Cowen | Buy | — |
| Aug 1, 2024 | TD Cowen | Buy | — |
| Apr 16, 2024 | TD Cowen | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 5, 2026
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 22.22 percent increase over losses of $(0.09) per share
Benzinga · Jun 17, 2026
Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expected results and announcing a $300 million share buyback.
Yahoo · Jun 9, 2026
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
SeekingAlpha · Jun 8, 2026
2026-06-08. The following slide deck was published by Standard BioTools Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LAB.
